Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA1/2 Mutation”

130 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 130 results

Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Not applicableEnded earlyNCT01103128
What this trial is testing

Validation of a Mouse Model of Pancreatic Carcinogenesis

Who this might be right for
Pancreatic Cancer
Columbia University 450
Testing effectiveness (Phase 2)Study completedNCT01898312
What this trial is testing

BRCA1/2 and Effect of Mifepristone on the Breast

Who this might be right for
Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2
Karolinska Institutet 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT02571725
What this trial is testing

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
New Mexico Cancer Research Alliance 50
Not applicableStudy completedNCT05305001
What this trial is testing

Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico

Who this might be right for
Pancreatic CancerPancreatic Adenocarcinoma
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 107
Testing effectiveness (Phase 2)Active Not RecruitingNCT05498272
What this trial is testing

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Who this might be right for
Prostate CancerBRCA1 MutationBRCA2 Mutation+2 more
Rana McKay, MD 32
Testing effectiveness (Phase 2)Ended earlyNCT03499353
What this trial is testing

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Who this might be right for
Early Breast Cancer
Pfizer 61
Large-scale testing (Phase 3)Looking for participantsNCT06380751
What this trial is testing

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 788
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Early research (Phase 1)Study completedNCT04991480
What this trial is testing

ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced CancerMetastatic CancerBreast Cancer
Artios Pharma Ltd 93
Early research (Phase 1)Study completedNCT00892736
What this trial is testing

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Who this might be right for
Basal-Like Breast CarcinomaBRCA1 Mutation CarrierBRCA2 Mutation Carrier+14 more
National Cancer Institute (NCI) 98
Testing effectiveness (Phase 2)Study completedNCT01540565
What this trial is testing

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierOvarian Epithelial Tumor+3 more
National Cancer Institute (NCI) 52
Large-scale testing (Phase 3)Active Not RecruitingNCT06783140
What this trial is testing

Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

Who this might be right for
Pancreatic Cancer, Advanced or MetastaticBRCA1/2 MutationPALB2 Gene Mutation
University Health Network, Toronto 10
Testing effectiveness (Phase 2)Ended earlyNCT02034916
What this trial is testing

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 84
Not applicableStudy completedNCT02154633
What this trial is testing

Lessons Learned From the Family Gene Toolkit

Who this might be right for
Women With BRCA 1 or BRCA 2 MutationNon-tested Female Family Members
University of Michigan 13
Early research (Phase 1)Active Not RecruitingNCT05787587
What this trial is testing

PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+6 more
IDEAYA Biosciences 216
Not applicableNot Yet RecruitingNCT07764744
What this trial is testing

Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants

Who this might be right for
Ovarian NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation+2 more
Weill Medical College of Cornell University 70
Testing effectiveness (Phase 2)Study completedNCT01074970
What this trial is testing

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Who this might be right for
Breast Cancer
Hoosier Cancer Research Network 135
Testing effectiveness (Phase 2)UnknownNCT03337087
What this trial is testing

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Who this might be right for
Metastatic Biliary Tract CarcinomaMetastatic Colorectal CarcinomaMetastatic Gastroesophageal Junction Adenocarcinoma+6 more
Academic and Community Cancer Research United 18
Next Page